A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01597401
Recruitment Status : Completed
First Posted : May 14, 2012
Last Update Posted : January 8, 2018
SAIC-Frederick, Inc.
Therapeutics for Rare and Neglected Diseases (TRND)
QS Pharma
National Chung Cheng University
Infrared Imaging and Thermometry Unit, Biomedical Engineering and Physical Science Shared Resource (NIBIB)
ClinPharm Consulting, LLC
Ricerca Biosciences LLC
National Heart, Lung, and Blood Institute (NHLBI)
Cato Research
Information provided by (Responsible Party):
Shire ( Baxalta now part of Shire )

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : June 7, 2013
  Actual Study Completion Date : June 7, 2013